2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - La Nouvelle A-B
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Combination Therapy, Adverse Events, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Adult
PAPER

821 Acute degradation of MAF and IRF4 reveals an enhancer-based cooperative oncogenic chromatin network in multiple myeloma.

Qizhen Jia, Pierangela Sabbattini, PhD2, Katrina Fordwor-Hepburn, MD3, Nikolaos Trasanidis, MSc, BSc4, Sophie S Ball5, Yiming Huang6, Wenqi Gong7, Harry Whitwell, Dr.8, Irene Roberts, MD9, Alexia Katsarou10, Aristeidis Chaidos, MD, PhD11, Nick T Crump, PhD12, Anastasios Karadimitris13
1 Imperial College London, London, United Kingdom
2 Imperial College London, London, United Kingdom
3 Imperial College London, London, United Kingdom
4 Imperial College London, London, United Kingdom
5 Imperial College London, London, United Kingdom
6 Imperial College London, London, United Kingdom
7 Imperial College London, London, United Kingdom
8 National Phenome Centre and Imperial Clinical Phenotyping Centre, London, United Kingdom
9 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
10 Imperial College London, London, United Kingdom
11 Imperial College London, London, United Kingdom
12 Imperial College London, London, United Kingdom
13 Imperial College London, London, United Kingdom

Background

MAF is aberrantly expressed in a subset of multiple myeloma (MM) through juxtaposition to the IgH enhancers and is associated with high-risk disease. Our previous work identified MAF as a pioneer transcription factor that cooperates with the plasma-cell lineage transcription factor IRF4 to activate inactive chromatin and establish the MAF-dependent oncogenic programme. However, whether MAF and IRF4 depend on one another to sustain oncogenic transcription remains unknown. To address this, we developed inducible degradation models to define the individual and shared regulatory functions of MAF and IRF4 in MM.

Methods

CRISPR-Cas9-mediated homology-directed repair was used to introduce an FKBP-HA degron tag at the endogenous MAF or IRF4 loci in MM.1S cells. Protein degradation was induced with the VHL-recruiting degrader dTAG-V1 and validated by immunoblotting and flow cytometry. Cell growth and competitive fitness were measured following MAF depletion. RNA-seq was performed after 24 hours of dTAG-V1 or vehicle treatment. Changes in MAF and IRF4 occupancy, histone modifications and chromatin accessibility were assessed using ChIP-seq and ATAC-seq. ChIPmentation profiling of MAF, IRF4, and H3K27ac was also performed in primary MM samples with MAF translocations. BETA was used to integrate ChIP-seq and RNA-seq data and identify direct regulatory targets. Micro-Capture-C was used to map enhancer–promoter interactions at selected MAF/IRF4-regulated loci.

Results

Acute degradation of FKBP-HA-MAF was rapid and sustained, markedly impairing MM.1S proliferation and survival. MAF depletion caused extensive transcriptional changes, predominantly downregulation of genes involved in cell-cycle progression, chromosome segregation, DNA replication, DNA repair and MYC-associated transcriptional programmes.

ChIP-seq identified 4,387 MAF-bound loci. Integration with the MAF degradation-sensitive transcriptome identified 160 genes predicted to be directly activated by MAF, that were enriched in myeloma survival and cell-cycle programmes.

IRF4 ChIP-seq identified 44,352 binding sites, of which 9% were co-bound by MAF, while nearly all MAF-bound regions were also occupied by IRF4. MAF depletion caused IRF4 redistribution, with loss of 1,272 and gain of 3,612 IRF4-binding events. Only one gained site was co-bound by MAF, whereas nearly 70% of lost IRF4 sites were MAF co-bound, and 70% of these were located at enhancers. Gene Set Enrichment Analysis showed that MAF-IRF4 co-binding regulates genes involved in myeloma survival and cell-cycle programmes. Although MAF depletion caused only a mild global reduction in chromatin accessibility, accessibility was profoundly reduced at MAF-bound and MAF-IRF4 co-bound sites. Similarly, only 10% of H3K27ac peaks changed globally, but a marked loss occurred at MAF-bound and MAF-IRF4 co-bound regions, predominantly at enhancers.

To address the reverse dependency, IRF4 was acutely degraded and MAF chromatin occupancy was assessed. After IRF4 depletion, MAF binding was reduced at 2,509 sites and increased at 323 sites. Of the lost MAF-bound loci, 93% were co-bound with IRF4 and were predominantly located at active enhancers. Together, these findings indicate that MAF and IRF4 depend on one another for chromatin binding and cooperate to maintain enhancer accessibility and activity. ChIPmentation in primary MAF-translocated MM samples confirmed co-occupancy of MAF and IRF4 at H3K27ac-marked regulatory regions. Micro-Capture-C analysis of selected MAF/IRF4-regulated loci is in progress to define how depletion of either factor at enhancers affects interactions with target promoters.

Conclusion

MAF and IRF4 form a regulatory network that sustains MM cell fitness, proliferative transcription and enhancer states. Acute depletion revealed shared control of cell-cycle and chromosome-segregation genes, reciprocal dependence of chromatin occupancy, and maintenance of accessibility at co-bound enhancers. Validation of MAF-IRF4 co-binding at H3K27ac-marked regions in primary MAF-translocated MM samples supports the relevance of this network. Disrupting MAF-IRF4-associated transcriptional complexes may represent a therapeutic strategy in MAF-driven MM.

Qizhen Jia: No relevant conflicts of interest to declare.